Cotinga Pharmaceuticals Inc COTQF

RE:About recent announcemnt

[DIYGuy]

“Today, the Company announced it has established a recommended Phase 2 dose for COTI-2 in ovarian cancer of 1.0 mg/kg orally 5 days per week.”

So, looking at this wording implies you can have a different recommended dose for different types of cancer and I guess that is why we are in HNSCC phase 1 trial and not just jumping into phase 2. Maybe they are trying to get a higher (more effective) dose for HNSCC.

“In this first Phase 1 trial, 15 patients were evaluated for secondary and exploratory outcome measures, including various signals of efficacy measured using RECIST criteria1. Eleven (11) of the 15 patients evaluated for secondary and exploratory outcome measures had ovarian cancer. Twelve (12) of the 15 patients evaluated for secondary and exploratory outcome measures were genetically-profiled; 9 of the 12 genetically-profiled patients exhibited a variety of p53 mutations. One (1) of the 15 patients evaluated for secondary and exploratory outcome measures was determined to have overall stable disease. Four (4) of the 15 patients evaluated for secondary and exploratory outcome measures were determined to have progressing disease, but stable target lesions; target lesions are lesions specifically chosen and measured to assess whether a patient's tumor burden is increasing or decreasing. Five (5) of the 15 patients evaluated for secondary and exploratory outcome measures were determined to have progressing disease but stable non-target tumors; stable non-target tumors indicate that no new lesions were identified. Patients were also assessed for Cancer Antigen-125 (CA-125) levels, a protein found in the blood which can be used to monitor certain cancers. One patient in the study was observed to have a decrease in CA-125.”

So, we have something to analyze. My guess is the majority of investors or potential investors would not understand this. Time to go back to school for algebra to take Venn diagrams again.  Some organic chemistry wouldn’t hurt either. It doesn’t spell out the patients that had p53 mutation and where they fit into the results. 

Anyone going to the meeting tomorrow please post any relevant details. Would be much appreciated.